NeuroPace (NPCE) Stock Price, News & Analysis

Company Overview

NeuroPace, Inc. is a medical device company based in Mountain View, California, that develops innovative neuromodulation systems for the treatment of neurological disorders. Founded in the late 1990s out of research at Stanford University, the company’s mission centers on delivering closed-loop, “smart” therapies that monitor and respond to electrical activity in the brain. In 2020, NeuroPace completed its initial public offering and now trades on the NASDAQ under the ticker NPCE.

The company’s flagship product, the RNS® System, is an implantable device designed for adults with medically refractory focal epilepsy. The system continuously records brain activity, detects abnormal electrical patterns that may lead to seizures, and delivers targeted stimulation to disrupt seizure activity before clinical symptoms arise. The RNS® System is implanted in the skull and connected directly to seizure foci via intracranial leads, offering a personalized therapy approach based on each patient’s unique seizure patterns.

NeuroPace holds regulatory approvals for the RNS® System in the United States and has obtained CE Mark certification for use in select European countries. The company works closely with leading epilepsy centers and neurosurgeons to support patient screening, surgical training, and postoperative programming. In addition to its clinical efforts, NeuroPace invests in ongoing research collaborations aimed at expanding closed-loop neuromodulation into other therapeutic areas, such as movement disorders and psychiatric conditions.

Guided by a leadership team with deep expertise in neurology, engineering and regulatory affairs, NeuroPace continues to refine its technology platform and explore new applications for responsive neurostimulation. The company maintains its headquarters in Silicon Valley and partners with hospitals, healthcare systems and academic institutions to enhance patient access and advance the scientific understanding of brain-responsive therapies.

Key Stats

• Today's Range: $16.72 to $18.20
• 50-Day Range: $12.84 to $17.25
• 52-Week Range: $7.56 to $18.98
• Volume: 135,375 shs
• Average Volume: 203,279 shs
• Market Capitalization: $615.00 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $18.67
• Consensus Rating: Moderate Buy

NeuroPace Stock Analysis - MarketRank™

NeuroPace scored higher than 28% of companies evaluated by MarketBeat, and ranked 721st out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.8 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

NeuroPace has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 2 strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.

Upside/Downside

The consensus price target for NeuroPace is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

NeuroPace has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for NeuroPace are expected to grow in the coming year, from ($0.51) to ($0.09) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of NeuroPace is -25.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of NeuroPace is -25.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

NeuroPace has a P/B Ratio of 30.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.43% of the float of NeuroPace has been sold short.

Short Interest Ratio / Days to Cover

NeuroPace has a short interest ratio ("days to cover") of 6.64.

Change versus previous month

Short interest in NeuroPace has recently decreased by 3.37%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

NeuroPace does not currently pay a dividend.

Dividend Growth

NeuroPace does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 3 news articles for NeuroPace this week, compared to 3 articles on an average week.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, NeuroPace insiders have not sold or bought any company stock.

Percentage Held by Insiders

20.50% of the stock of NeuroPace is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

78.83% of the stock of NeuroPace is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

NPCE Stock Analysis - Frequently Asked Questions

How have NPCE shares performed this year?

NeuroPace's stock was trading at $15.44 on January 1st, 2026. Since then, NPCE shares have increased by 11.0% and is now trading at $17.14.

How were NeuroPace's earnings last quarter?

NeuroPace, Inc. (NASDAQ:NPCE) released its earnings results on Tuesday, March, 3rd. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.06. The company earned $26.59 million during the quarter, compared to the consensus estimate of $24.79 million. NeuroPace had a negative net margin of 21.47% and a negative trailing twelve-month return on equity of 105.67%.
Read the conference call transcript.

When did NeuroPace IPO?

NeuroPace (NPCE) raised $85 million in an initial public offering (IPO) on Thursday, April 22nd 2021. The company issued 5,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO and Wells Fargo and SVB Leerink were co-managers.

Who are NeuroPace's major shareholders?

Top institutional investors of NeuroPace include Bank of New York Mellon Corp (0.15%), Hsbc Holdings PLC (0.09%) and SG Americas Securities LLC (0.03%). Insiders that own company stock include Orbimed Advisors Llc, Martha Morrell and Ltd Kck.
View institutional ownership trends.

How do I buy shares of NeuroPace?

Shares of NPCE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of NeuroPace own?

Based on aggregate information from My MarketBeat watchlists, some other companies that NeuroPace investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), e.l.f. Beauty (ELF) and Jabil (JBL).

Company Calendar

• Last Earnings: 3/03/2026
• Today: 5/06/2026
• Next Earnings (Estimated): 5/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:NPCE
• CIK: 1528287
• Web: www.neuropace.com
• Phone: 650-237-2700
• Fax: N/A
• Employees: 170
• Year Founded: 1997

Price Target and Rating

• Average Price Target for NeuroPace: $18.67
• High Price Target: $22.00
• Low Price Target: $16.00
• Potential Upside/Downside: +3.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.88
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.66)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$21.47 million
• Net Margins: -21.47%
• Pretax Margin: -21.47%
• Return on Equity: -105.67%
• Return on Assets: -20.01%

Debt

• Debt-to-Equity Ratio: 3.09
• Current Ratio: 5.28
• Quick Ratio: 4.33

Sales & Book Value

• Annual Sales: $99.99 million
• Price / Sales: 6.13
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.57 per share
• Price / Book: 31.65

Miscellaneous

• Outstanding Shares: 33,950,000
• Free Float: 26,990,000
• Market Cap: $612.46 million
• Optionable: Optionable
• Beta: 1.92